ArticleAntimicrobial agents and chemotherapy2021
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.Journal of medicinal chemistry · 2026Article
- Cytochrome P450-Mediated Metabolism of AntimycobacterialACS infectious diseases · 2026Article
- The Spermidine Synthase Gene as a Reporter of Transcription Inhibition inInternational journal of molecular sciences · 2026Article
- The Quantification of Drug Accumulation within Gram-Negative Bacteria.ACS infectious diseases · 2026Article
- Loss-of-Function Mutations in the Penicillin-Binding Protein PonA1 Confer Agar-Dependent Resistance to Durlobactam inAntibiotics (Basel, Switzerland) · 2025Article
- A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference inACS infectious diseases · 2025Article
- Nanotherapies based on bacterial metabolism: Mechanisms, design and application.Materials today. Bio · 2025Review
- Next-generation rifamycins for the treatment of mycobacterial infections.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Efflux pumps and membrane permeability contribute to intrinsic antibiotic resistance in Mycobacterium abscessus.PLoS pathogens · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA ofAntimicrobial agents and chemotherapy · 2024Article
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Synthesis and in vitro Metabolic Stability of Sterically Shielded Antimycobacterial Phenylalanine Amides.ChemMedChem · 2024Article
- Exploring antibiotic resistance mechanisms inFrontiers in microbiology · 2024Review
- Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.Microbiology spectrum · 2023Article
- ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerantAntimicrobial agents and chemotherapy · 2023Article
- CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus.Microbiology spectrum · 2023Article
- Synthesis and Characterization of Phenylalanine Amides Active againstJournal of medicinal chemistry · 2023Article
- Article
- Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.Angewandte Chemie (International ed. in English) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Rifampicin is an effective drug for treating tuberculosis (TB) but is not used to treat Mycobacterium abscessus infections due to poor
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.